Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

OGEN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: June 09, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Oragenics Inc (OGEN)

Based on 7 analysts giving stock ratings to Oragenics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
29
Buy
57
Hold
14
Sell
0
Strong Sell
0
Oragenics Inc

Oragenics Inc. Stock Analysis OGEN

United States Health Care Nano Cap Report:
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Lakewood Ranch, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Read More

Oragenics Inc (OGEN) Chart

Key Statistics of Oragenics Inc (OGEN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.59$0.60

Today's Open

$0.60

Volume

24.26K

P/E Ratio (TTM)

-

52 Week Range

$0.50$4.19

Market Cap

2.66M

Avg. Volume

53.83K

Dividend Yield

-

Financial Metrics & Statements of Oragenics Inc (OGEN)

FAQ's for Oragenics Inc (OGEN)

  • According to Musaffa’s Shariah screening methodology, Oragenics Inc (OGEN) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Oragenics Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Oragenics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Oragenics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Oragenics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Oragenics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.